NASDAQ:SPRO Spero Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.83 +0.09 (+12.21%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.74▼$0.8450-Day Range$0.74▼$5.5252-Week Range$0.73▼$19.87Volume218,153 shsAverage Volume459,249 shsMarket Capitalization$27.16 millionP/E RatioN/ADividend YieldN/APrice Target$28.33 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spero Therapeutics Stock Forecast (MarketRank)Analyst RatingHold2.40 Rating ScoreUpside/Downside3,324.4% Upside$28.33 Price TargetShort InterestHealthy5.83% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.38Based on 7 Articles This WeekInsider TradingAcquiring Shares$208.17 K Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.88) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.40 out of 5 starsMedical Sector132nd out of 1,428 stocksPharmaceutical Preparations Industry53rd out of 682 stocks 3.2 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.33, Spero Therapeutics has a forecasted upside of 3,324.4% from its current price of $0.83.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.83% of the float of Spero Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 8.97%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 1.9 News and Social Media Coverage News SentimentSpero Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Spero Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $208,169.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.45% of the stock of Spero Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.36% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($2.88) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Spero Therapeutics (NASDAQ:SPRO)Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More SPRO Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200 Day Moving Average of $7.22June 27, 2022 | investing.comSpero Therapeutics Plummets 15% on FDA's CRL for Tebipenem HBr New Drug ApplicationJune 27, 2022 | nasdaq.comU.S. FDA declines to approve Spero's urinary tract infection drugJune 27, 2022 | seekingalpha.comFDA rejects Spero's application seeking approval of its urinary tract infection tabletsJune 27, 2022 | finance.yahoo.comSpero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug ApplicationJune 27, 2022 | finance.yahoo.comUPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drugJune 24, 2022 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200-Day Moving Average of $7.76June 17, 2022 | apnews.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the FirmJune 16, 2022 | apnews.comSpero Therapeutics, Inc. Investor News: Robbins LLP is Investigating Spero Therapeutics, Inc. (SPRO) on Behalf of ShareholdersJune 16, 2022 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Share Price Crosses Below Two Hundred Day Moving Average of $8.30June 10, 2022 | apnews.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)June 10, 2022 | morningstar.comSPRO LAWSUIT ALERT: Levi & Korsinsky Notifies Spero Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 9, 2022 | americanbankingnews.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Forecasted to Post FY2023 Earnings of ($1.98) Per ShareJune 8, 2022 | benzinga.comSPRO ALERT: The Klein Law Firm Announces a Lead...June 6, 2022 | tmcnet.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) InvestorsJune 3, 2022 | benzinga.comCLASS ACTION UPDATE for AMZN, SPRO and IONQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJune 3, 2022 | apnews.comThe Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of InvestorsJune 2, 2022 | apnews.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of InvestorsJune 2, 2022 | apnews.comSpero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law FirmMay 31, 2022 | apnews.comShareholder Alert: Robbins LLP Informs Investors of Class Action Against Spero Therapeutics, Inc. (SPRO)May 31, 2022 | apnews.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. (SPRO)May 30, 2022 | apnews.comSpero Class Action Complaint Filed: Johnson Fistel, Globally Recognized Law Firm Encourages Shareholders to Submit Their LossesMay 27, 2022 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the FirmMay 26, 2022 | apnews.comPomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPROMay 23, 2022 | nasdaq.comBuying Power of Binance Coin vs. Spero Therapeutics at New 52-Week HighSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees146Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$28.33 High Stock Price Forecast$70.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+3,324.4%Consensus RatingHold Rating Score (0-4)2.4 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89.76 million Net Margins-792.03% Pretax Margin-792.03% Return on Equity-116.93% Return on Assets-71.00% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$18.26 million Price / Sales1.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.30Miscellaneous Outstanding Shares32,820,000Free Float28,407,000Market Cap$27.16 million OptionableOptionable Beta2.04 Spero Therapeutics Frequently Asked Questions Should I buy or sell Spero Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Spero Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares. View analyst ratings for Spero Therapeutics or view top-rated stocks. What is Spero Therapeutics' stock price forecast for 2022? 5 analysts have issued 1-year target prices for Spero Therapeutics' shares. Their SPRO stock forecasts range from $5.00 to $70.00. On average, they predict Spero Therapeutics' stock price to reach $28.33 in the next twelve months. This suggests a possible upside of 3,324.4% from the stock's current price. View analysts' price targets for Spero Therapeutics or view top-rated stocks among Wall Street analysts. How has Spero Therapeutics' stock price performed in 2022? Spero Therapeutics' stock was trading at $16.01 on January 1st, 2022. Since then, SPRO shares have decreased by 94.8% and is now trading at $0.8274. View the best growth stocks for 2022 here. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Spero Therapeutics. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings results on Monday, May, 16th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.14. The firm earned $2.07 million during the quarter, compared to analysts' expectations of $2.85 million. Spero Therapeutics had a negative net margin of 792.03% and a negative trailing twelve-month return on equity of 116.93%. During the same period in the prior year, the company posted ($0.66) EPS. View Spero Therapeutics' earnings history. Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the following people: Dr. Ankit Mahadevia M.D., MBA, Co-Founder, Pres, CEO & Director (Age 41, Pay $924.28k) (LinkedIn Profile)Mr. Satyavrat Shukla C.F.A., CFO & Treasurer (Age 50, Pay $788.84k)Ted Jenkins, VP & Head of Investor RelationsMs. Tamara Lynn Joseph L.L.M., Chief Legal Officer (Age 59)Mr. James P. Brady, Chief Human Resource OfficerMr. Timothy Keutzer, Chief Devel. Officer (Age 54)Dr. Ian A. Critchley, Head of Clinical MicrobiologyDr. Susannah Walpole Ph.D., Head of Clinical OperationsDr. Angela Talley, Sr. VP of Clinical Devel. What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Akouos (AKUS), Paratek Pharmaceuticals (PRTK), Immunic (IMUX), Assembly Biosciences (ASMB), Homology Medicines (FIXX), PDS Biotechnology (PDSB), Entasis Therapeutics (ETTX), Leap Therapeutics (LPTX), Decibel Therapeutics (DBTX), DURECT (DRRX), Enochian Biosciences (ENOB), Daré Bioscience (DARE), Annovis Bio (ANVS), Checkpoint Therapeutics (CKPT) and ImmunoPrecise Antibodies (IPA). View all of SPRO's competitors. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $0.83. How much money does Spero Therapeutics make? Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $27.16 million and generates $18.26 million in revenue each year. The company earns $-89.76 million in net income (profit) each year or ($3.24) on an earnings per share basis. How many employees does Spero Therapeutics have? Spero Therapeutics employs 146 workers across the globe. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for Spero Therapeutics is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com. This page (NASDAQ:SPRO) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
